No insider purchase over the last 90 days. The latest, by 에이치투자조합, was filed 07 Apr 2026.
Genesystem Co., Ltd.: what insiders have been doing
Genesystem Co., Ltd. belongs to the Health Care sector. Filings by its managers are published through DART (FSS). In the past year (1 November 2025 to 1 November 2026), 12 filings came from 6 insiders.
Open-market activity splits into 5 purchases totalling €8.1M and 6 sales totalling €510k; 2 insiders sit on the buying side and 3 insiders on the selling side. The totals exclude 4 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 1 board member. Biggest ticket of the year: €2.6M, bought by 에이치투자조합 and made public on 7 April 2026 (12.5% of market cap).
The data flag 2 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The latest purchase dates back some time: it was published 216 days ago, on 7 April 2026. Filings reach the DART (FSS) feed a median of 10 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Compared with its exchange (2,655 companies, median 7 filings), a count of 12 filings is above the norm. Our records for Genesystem Co., Ltd. go back to 2021, with 20 purchases and 10 sales on the open market in total.
In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Who traded when
BuySale+1 other insider
Since the insiders bought
- -36.2%Entry ₩6,800 · Close 30 Oct 2026 ₩4,340
- -32.5%Entry ₩6,430 · Close 30 Oct 2026 ₩4,340
- -51.1%Entry ₩8,970 · Close at T+365 ₩4,385
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 715,138 shares@ ₩4,195.008.21% mcap39.7% of flowShareKRXDART:20260407002143Canonical exit: 30 Jun 2026 (T+90)
- 715,138 shares12.49% mcap60.3% of flowKRXDART:20260407002147Canonical exit: 29 Jun 2026 (T+90)
- 125,006 shares2.18% mcap89.2% of flowKRXDART:20260407002140
- 15,006 shares@ ₩4,395.000.18% mcap100.0% of flowShareKRXDART:20260324000216Canonical exit: 18 Jun 2026 (T+90)
- 15,002 shares0.26% mcap10.8% of flowKRXDART:20260324000234
- ●Executives0DART
- 715,138 shares@ ₩4,195.008.91% mcap46.8% of flowShareKRXDART:20260309001151Canonical exit: 28 May 2026 (T+90)
- 715,138 shares10.14% mcap53.2% of flowKRXDART:20260309001152Canonical exit: 28 May 2026 (T+90)
- 192,006 sharesKRXDART:20260219002608
- 15,000 sharesKRXDART:20260106000561
- 144,214 sharesKRXDART:20260102000380
- 81,032 sharesKRXDART:20251202000315
- 74,771 sharesKRXDART:20250709000170
- 2,004 sharesKRXDART:20250702000236
- 30,000 sharesShareKRXDART:20250702000223Canonical exit: 30 Sept 2025 (T+90)
- 9,179 sharesKRXDART:20250409001850Canonical exit: 24 Jun 2025 (T+90)
- 63,980 sharesKRXDART:20250109000150
- 16,500 sharesShareKRXDART:20241206000038Canonical exit: 6 Mar 2025 (T+90)
- 0KRXDART:20241206000048
- 4,502 sharesShareKRXDART:20241206000043Canonical exit: 6 Mar 2025 (T+90)
- ●Executives0DART
- ●Executives0DART
- 400,000 sharesKRXDART:20240117000210
- 146,442 sharesKRXDART:20240108000284Canonical exit: 4 Jan 2024 (T+90)
- 0KRXDART:20231222000446
25 of 56 declarations
About Genesystem Co., Ltd.
진시스템 is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX. It specializes in developing technological solutions for the medical field.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
